Person: ÖZTÜRK CİVELEK, DİLEK
46 results
Search Results
Now showing 1 - 10 of 46
Publication Metadata only Dosing-Time Dependent Reproductive Toxicity of Everolimus in Male Mice.(2016-05-25) Öztürk, Narin; ÖZTÜRK, DİLEK; Pala Kara, Zeliha; Kaptan, Engin; Li, Xiao Mei; Levi, Francis; Okyar, Alper; ÖZTÜRK CİVELEK, DİLEKPublication Metadata only Dosing-time dependent testicular toxicity of everolimus in mice.(2021-07-07T00:00:00Z) Ozturk, Narin; Ozturk Civelek, DİLEK; Sancar, Serap; Kaptan, Engin; Pala Kara, Zeliha; Okyar, Alper; ÖZTÜRK CİVELEK, DİLEKPublication Metadata only Synthesis and Cytotoxic Activity of New Sorafenib / Ruthenium Complexes,(2020-02-27T00:00:00Z) Zengin Kurt, Belma; Çakma, Elmas Begüm; Öztürk, Dilek; Dağ, Aydan; Benkli, Kadriye; ZENGİN KURT, BELMA; ÖZTÜRK CİVELEK, DİLEK; DAĞ, AYDANPublication Metadata only SS-73: Everolimusun kronofarmakokinetiği: Uygulama zamanı, cinsiyet ve beslenme durumunun etkisi(2019-11-03T00:00:00Z) Öztürk, Ferdi; ÖZTÜRK, DİLEK; Yasemin Kübra, Akyel; PALA KARA, ZELİHA; OKYAR, ALPER; ÖZTÜRK CİVELEK, DİLEKPublication Metadata only Şekil Hafızalı ve Kendini Onarabilen Hidrojeller(2021-10-08T00:00:00Z) Kılıç, Hüsna; Tuncaboylu, Deniz Ceylan; Argun, Aslı; Öztürk Civelek, Dilek; TUNCABOYLU, DENIZ CEYLAN; ÖZTÜRK CİVELEK, DİLEK.Publication Metadata only PS-01: Zamana bağlı everolimus uygulamasının dişi ve erkek farelerde P-glikoprotein ekspresyonuna etkisi(2019-11-03T00:00:00Z) Öztürk, Ferdi; Yasemin Kübra, Akyel; ÖZTÜRK, DİLEK; ÖZTÜRK, NARİN; PALA KARA, ZELİHA; OKYAR, ALPER; ÖZTÜRK CİVELEK, DİLEK; GÖNCÜ, BEYZA SERVETPublication Metadata only The Association of ABCC5 and ABCC11 Polymorphisms with The Pharmacokinetics of 5-FU in Advanced Gastric Cancer Patients(2020-09-01T00:00:00Z) Akyel, Yasemin Kübra; Pala Kara, Zeliha; Öztaş, Ezgi; Öztürk, Dilek; Turna, Zeynep Hande; Okyar, Alper; Özhan, Gül; ÖZTÜRK CİVELEK, DİLEKPublication Metadata only Synthesis and Cytotoxic Activity of Coumarin-Thymol Derivatives(2018-06-30) ZENGİN KURT, BELMA; Çelebi, Gülşen; ÖZTÜRK, DİLEK; SONMEZ, FATIH; ZENGİN KURT, BELMA; ÖZTÜRK CİVELEK, DİLEKPublication Metadata only Evaluation of Metabolites Produced by Fungal Biotransformation of Apigenin and Fisetin and Their Cytotoxic Activities(2020-03-01T00:00:00Z) GAZİOĞLU, IŞIL; Erdoğan, Oğuz; YANIKOĞLU, RABİA SARE; ÖZTÜRK, DİLEK; GAZİOĞLU, IŞIL; YANIKOĞLU, RABİA SARE; ÖZTÜRK CİVELEK, DİLEKPublication Open Access The Effects of P-glycoprotein Inhibitor Zosuquidar on the Sex and Time-Dependent Pharmacokinetics of Parenterally Administered Talinolol in Mice.(2020-10-10T00:00:00Z) Kara, ZP; Ozturk, DİLEK; Ozturk, N; Okyar, A; ÖZTÜRK CİVELEK, DİLEKP-glycoprotein (P-gp) is an efflux protein that forms a tissue barrier and plays a role in the pharmacokinetics of drugs, limiting the influx of them and other xenobiotics into the cells, as expressed in various tissues such as liver, brain, intestinal mucosa and kidneys. Circadian clock controls many biological functions in mammals including xenobiotic metabolism and detoxification. Circadian rhythms of biological functions may affect the pharmacokinetics, and thus efficacy and/or toxicity of drugs. Aim of this study is to determine how the intraperitoneally administered pharmacokinetics of talinolol, as the probe substrate of P-gp, will change depending on the circadian time and sex in the presence of P-gp inhibitor zosuquidar. 20 mg/kg talinolol with or without 30 mg/kg zosuquidar was administred intraperitoneally to male and female mice at day period (ZT3) and night period (ZT15). Plasma and tissue concentrations of talinolol were determined by using validated HPLC/UV method. The protein levels of P-gp in the liver and small intestine in male and female mice were determined by PCR and Western blot techniques. P-gp protein levels in liver and ileum tissues were not different in female mice but higher in ZT15 as compared to ZT3 in male mice (p<0.05). There was no statistically significant difference in talinolol concentration depending on time and sex in the plasma and liver. There was significant time-dependent difference between ZT3 and ZT15 groups in ileum AUC0–5 h of talinolol (p<0.01). Talinolol plasma and liver AUC0–5 h were increased by zosuquidar administration regardless of dosing-time and sex (p<0.05). Our study findings are considerable in terms of revealing changes in pharmacokinetic profiles of P-gp substrates due to the time of administration in combination with P-gp inhibitors/modulators in managing polypharmacy.